These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Treatment of impaired cognition with nootropic drugs: nicergoline versus the state of the art. Fariello RG Funct Neurol; 1997; 12(3-4):221-5. PubMed ID: 9218984 [No Abstract] [Full Text] [Related]
5. [Reality of pharmacotherapy in nursing home patients with dementia. Results of a new field study of 23 nursing homes]. Hallauer J Krankenpfl J; 2005; 43(7-10):206. PubMed ID: 16515277 [No Abstract] [Full Text] [Related]
6. Outcomes for clinical trials in mild-to-moderate dementia to evaluate drugs with presumably symptomatic effects. Frolich L J Nutr Health Aging; 2007; 11(4):357-8. PubMed ID: 17653499 [No Abstract] [Full Text] [Related]
8. On the horizon: pathways for drug development in Alzheimer's disease. Hake AM; Farlow MR Clin Geriatr Med; 2004 Feb; 20(1):141-52. PubMed ID: 15062492 [No Abstract] [Full Text] [Related]
9. Objective psychometric tests in clinical trials of dementia drugs. Position paper from the International Working Group on Harmonization of Dementia Drug Guidelines. Ferris SH; Lucca U; Mohs R; Dubois B; Wesnes K; Erzigkeit H; Geldmacher D; Bodick N Alzheimer Dis Assoc Disord; 1997; 11 Suppl 3():34-8. PubMed ID: 9305514 [No Abstract] [Full Text] [Related]
11. Translation issues in clinical trials of dementia drugs. Position paper from the International Working Group on Harmonization of Dementia Drug Guidelines. Feldman H; Anand R; Blesa R; Dubois B; Gray J; Homma A; Mohr E; Morris JC; Parys W; Raschig A; Robillard A Alzheimer Dis Assoc Disord; 1997; 11 Suppl 3():61-4. PubMed ID: 9305520 [No Abstract] [Full Text] [Related]
12. Clinical trials of treatment for noncognitive symptoms of dementia. Position paper from the International Working Group on Harmonization of Dementia Drug Guidelines. Homma A; Brodaty H; Bruno G; Cummings JL; Gilman S; Gracon S; McKeith IG Alzheimer Dis Assoc Disord; 1997; 11 Suppl 3():54-5. PubMed ID: 9305518 [No Abstract] [Full Text] [Related]
13. Efficacy and safety of memantine in moderate-to-severe Alzheimer disease: the evidence to date. Bullock R Alzheimer Dis Assoc Disord; 2006; 20(1):23-9. PubMed ID: 16493232 [TBL] [Abstract][Full Text] [Related]
14. [Therapy approaches in cerebral cognitive deficits--neuropsychiatric aspects]. Reisecker F Wien Med Wochenschr; 1996; 146(21-22):546-8. PubMed ID: 9092214 [TBL] [Abstract][Full Text] [Related]
16. [Dementia therapy. Colleagues are very reticent about using drugs]. MMW Fortschr Med; 2002 Apr; 144(17):50. PubMed ID: 12048856 [No Abstract] [Full Text] [Related]
17. Measuring cognitive change in Alzheimer's disease clinical drug trials. Harrison JE J Nutr Health Aging; 2007; 11(4):327-9. PubMed ID: 17653492 [TBL] [Abstract][Full Text] [Related]
19. Cognitive, global, and functional benefits of donepezil in Alzheimer's disease and vascular dementia: results from large-scale clinical trials. Passmore AP; Bayer AJ; Steinhagen-Thiessen E J Neurol Sci; 2005 Mar; 229-230():141-6. PubMed ID: 15760632 [TBL] [Abstract][Full Text] [Related]
20. Ethical issues in dementia drug development. Position paper from the International Working Group on Harmonization of Dementia Drug Guidelines. Post SG; Beerman B; Brodaty H; Gaines AW; Gauthier SG; Geldmacher DS; Hill S; Homma A; Rossor MN; Whitehouse PJ; Winblad B Alzheimer Dis Assoc Disord; 1997; 11 Suppl 3():26-8. PubMed ID: 9305511 [No Abstract] [Full Text] [Related] [Next] [New Search]